Literature DB >> 29899775

Extensive Cranial Nerves Involvement in Neurofibromatosis: A Rare Presentation.

Ashutosh Gupta1, Charu Gupta2, Monika Sachan1, Sandeep Singh1.   

Abstract

Neurofibromatosis type 2 is a rare neurocutaneous syndrome characterized by the development of multiple nervous system tumors. This disorder is also called multiple inherited schwannomas, meningiomas, and ependymomas syndrome. In this report, we discuss the clinical and magnetic resonance imaging findings in a 17-year-old patient with neurofibromatosis type 2, who had extensive cranial nerves involvement (3rd-12th cranial nerves) along with spinal involvement. It is very rare to find tumors affect nearly all cranial nerves (namely 3rd-12th nerves), and their association with meningiomas and intramedullary spinal cord tumors in the same patient.

Entities:  

Keywords:  Cranial nerves; MISME syndrome; neurofibromatosis

Year:  2018        PMID: 29899775      PMCID: PMC5982496          DOI: 10.4103/JPN.JPN_32_18

Source DB:  PubMed          Journal:  J Pediatr Neurosci        ISSN: 1817-1745


INTRODUCTION

Neurofibromatosis type 2 (NF2) is a rare autosomal-dominant disorder with an incidence of approximately 1:40,000 to 1:50,000 individuals, and equal gender predisposition.[1] Although a disease of adults, it could be evident in childhood and often gets unrecognized.[234] The disease has variable expression ranging from characteristic right and left vestibular schwannomas (VS), skin tumors, ocular abnormality, and other cranial and spinal tumors. Some have nonneoplastic lesions such as schwannosis, meningioangiomatosis, and glial hamartia. Prognosis depends on the grade of severity, and as the disease is progressive, patient should remain under surveillance. The affected individuals should be advised not to have children.

CASE REPORT

A 17-year-old male patient, product of non-consanguineous marriage, presented with complaints of weakness and wasting of left leg for 5 years, reduced hearing in both ears for 6 months, and weakness and wasting of left hand for 4 months. He had multiple nodules over the trunk, right knee, and left suboccipital region. There was no evidence of clinical manifestations of neurofibromatosis in his family members, when traced out upto 3 generations. There was no history of associated headache, fever, seizures, vomiting, unconsciousness, ataxia, vertigo, difficulty in vision, facial deviation, giddiness, nasal regurgitation of food, difficulty in speech, memory loss, neck pain, and urinary/fecal incontinence. On examination, the nodules were found to be non-tender, firm, well defined, irregular, and of variable sizes. There was also a suboccipital and postauricular swelling on the left side with no cough impulse. He had bilateral asymmetric sensorineural hearing loss, and left foot drop and pes cavus. On ophthalmological examination, the patient was found to have a visual acuity of 6/9 and 6/18, which did not improve with pinhole. He had manifest squint with no restriction of eye movements or diplopia or nystagmus. He had wasting in his left lower limb and left hand. He had generalized loss of deep tendon reflexes with preservation of superficial reflexes. Fasciculations were seen in both the calves. The patient also had sensory loss to touch/pain in L5 dermatomal region. However, joint position and vibration sense were intact. There were no signs of incoordination or any autonomic involvement. On ultrasonography of the abdomen, a hypoechoic lesion measuring 11×12mm was seen in pelvis indenting on the right wall of urinary bladder. On nerve conduction studies, demyelinating pattern was observed. Pure-tone audiometry confirmed bilateral sensorineural hearing, which was profound on the right and moderate on the left. Brainstem evoked response audiometry of the patient revealed no response on the right and only one wave on the left. Review of the contrast enhanced MR imaging of brain showed large multilobulated solid-cum-cystic lesion in cerebellar vermian region, which continued posteriorly into retrocerebellar, suboccipital, and brain stem region. It exhibited enhancement of its solid mural nodular component, which was compressing on brain stem, craniovertebral, and cervicomedullary junction [Figure 1]. There was also inhomogeneous patchy enhancement of both cerebellopontine (CP) angle region and prepontine region along the course of vestibulocochlear and trigeminal nerves, in Meckel cave region and bilateral cavernous sinus regions. Both vestibulocochlear nerves in CP angle regions were involved with intracanalicular extension of lesions [Figure 2A]. Paracavernous region exhibited bilateral involvement of multiple cranial nerves namely 3rd, 4th, and 6th; extra-calvarial retrocerebellar, retro-occipital, and suboccipital regions also exhibited multiple nodular-enhancing lesions of variable sizes representing neurocutaneous nodules with a possibility of plexiform involvement [Figure 2B]. Hydrocephalus presented with dilated temporal horns. Both optic nerves exhibited patchy enhancement along their course in orbital apex and optic tracts.
Figure 1

Axial post-contrast T1-weighted MRI showing homogeneously enhancing soft tissue along the course of right trochlear nerve entering the superior orbital fissure. Multiple homogeneously enhancing plexiform, soft-tissue masses are seen in bilateral cavernous sinus region obscuring the course of 3rd, 4th, 5th, and 6th cranial nerves

Figure 2

(A) Axial post-contrast T1-weighted MRI image showing homogeneously enhancing soft-tissue mass in bilateral cerebellopontine angle extending into internal auditory canal along the course of 7th and 8th cranial nerve complex giving a bilateral “ice-cream cone” appearance suggestive of schwannomas.: (B) Coronal post-contrast T1-weighted image with a heterogeneously enhancing solid cystic mass of the nucleus of lower cranial nerve projecting in extra-axial spaces compressing and distorting left cervicomedullary junction along the course of the 9th cranial nerve toward jugular foramen. In addition, multiple lobulated enhancing masses are seen along the course of exiting lower cranial nerves (10th, 11th, and 12th cranial nerves) in upper cervical foramina. (C) Sagittal T2-weighted image with mass in cervicomedullary region as detailed above. Additionally, intramedullary T2 hyperintensity at C2-C3 level (compatible with ependymoma or astrocytoma) with intradural extramedullary neural lesion at C6 level displacing the cord anteriorly with intramedullary hyperintensity is seen

Axial post-contrast T1-weighted MRI showing homogeneously enhancing soft tissue along the course of right trochlear nerve entering the superior orbital fissure. Multiple homogeneously enhancing plexiform, soft-tissue masses are seen in bilateral cavernous sinus region obscuring the course of 3rd, 4th, 5th, and 6th cranial nerves (A) Axial post-contrast T1-weighted MRI image showing homogeneously enhancing soft-tissue mass in bilateral cerebellopontine angle extending into internal auditory canal along the course of 7th and 8th cranial nerve complex giving a bilateral “ice-cream cone” appearance suggestive of schwannomas.: (B) Coronal post-contrast T1-weighted image with a heterogeneously enhancing solid cystic mass of the nucleus of lower cranial nerve projecting in extra-axial spaces compressing and distorting left cervicomedullary junction along the course of the 9th cranial nerve toward jugular foramen. In addition, multiple lobulated enhancing masses are seen along the course of exiting lower cranial nerves (10th, 11th, and 12th cranial nerves) in upper cervical foramina. (C) Sagittal T2-weighted image with mass in cervicomedullary region as detailed above. Additionally, intramedullary T2 hyperintensity at C2-C3 level (compatible with ependymoma or astrocytoma) with intradural extramedullary neural lesion at C6 level displacing the cord anteriorly with intramedullary hyperintensity is seen The MRI of the spine showed diffuse patchy heterogeneous hyperintense signal in T2-weighted sagittal images exhibited as subtle patchy enhancement in cervical and conus regions. There were multiple enhancing extradural nodular lesions with broad base at C6-C7 and D5-D6 levels, extending through both lateral neural regions and C5-C6 levels, and occupying right lateral aspect of spinal canal at D5-D6 levels. There was perineural involvement of caudal filum [Figure 2C]. Biopsy of the cutaneous lesion was consistent with neurofibroma [Figure 3]. Although the patient had no family history, the image findings of bilateral acoustic schwannomas, multiple intracranial meningiomas, and intramedullary tumor suggested the diagnosis of NF2.
Figure 3

Hematoxylin and eosin stain of the biopsy of the exophytic growth over the trunk, demonstrating picture consistent with neurofibroma

Hematoxylin and eosin stain of the biopsy of the exophytic growth over the trunk, demonstrating picture consistent with neurofibroma

DISCUSSION

We present a case of NF2 with bilateral multiple cranial nerve schwannomas involving 3rd, 4th, 5th, 6th, 8th, 9th, 10th, 11th, and 12th cranial nerves with early-onset polyneuropathy. Our case presents as left-sided weakness of both upper and lower limbs with bilateral hearing loss, which on workup was found to be a case of NF2 with bilateral multiple cranial nerve involvement. NF2 is a syndrome with bilateral VS, which is its pathognomonic and diagnostic criteria.[567] In its initial assessment, there are chances for these bilateral VS to be missed especially in patients without any family history. Of all the cases, 50% constitute first in family most probably because of the somatic mutation of NFT gene. Similar was the situation in our case, with no family history for the past three generations. NF2 has a varied clinical presentation with majority being presented with hearing loss accompanied or preceded by tinnitus because of the involvement of the 8th cranial nerve, which is similar to our case.[8] Studies have reported weakness and wasting of the muscle groups similar to poliolike features, years before detection of VS. Cases have also documented polyneuropathy in adulthood.[8] Weakness of lower limb muscles at the age of 12 years and polyneuropathy, occurring only in 3%–5%, in the form of involvement of hand muscles before adulthood could suggest the aggressiveness of the disease. The average age of onset of clinicoradiological findings has been found to be 18–24 years and in the range of birth to 70 years.[9] Being labeled as an adult-onset disease, it could get under-recognized in children.[9] This happened in our case too, when the patient developed first symptom in the form of lower limb weakness at the age of 12 years without any skin lesion or visual complaints.[9] Age of symptom onset is a very crucial feature, defining the prognosis of the disease. Early onset of initial symptoms has been reported to significantly decrease the survival rate.[10] Literature suggests that schwannomas can involve any of the cranial nerve except optical nerve.[5] We present this as a case of NF2 with extensive involvement (3rd, 4th, 5th, 6th, 8th, 9th, 10th, 11th, and 12th) of cranial nerves along with diffuse spinal involvement. The last reported case was by Pasricha et al.,[11] in which they had diagnosed lesions affecting seven cranial nerves in NF2. To the best of our knowledge, no other paper has reported such a case that involves tumors affecting nearly all cranial nerves (namely 3rd–12th nerves) with diffuse spinal involvement, their association with meningiomas and intramedullary spinal cord tumors, optic lesion, and early-onset polyneuropathy in the same patient.[11]

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  10 in total

Review 1.  Neurofibromatosis type 2.

Authors:  D G Evans; M Sainio; M E Baser
Journal:  J Med Genet       Date:  2000-12       Impact factor: 6.318

2.  Intramedullary and spinal canal tumors in patients with neurofibromatosis 2: MR imaging findings and correlation with genotype.

Authors:  N J Patronas; N Courcoutsakis; C M Bromley; G L Katzman; M MacCollin; D M Parry
Journal:  Radiology       Date:  2001-02       Impact factor: 11.105

3.  Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients.

Authors:  M Ruggieri; P Iannetti; A Polizzi; I La Mantia; A Spalice; O Giliberto; N Platania; A L Gabriele; V Albanese; L Pavone
Journal:  Neuropediatrics       Date:  2005-02       Impact factor: 1.947

Review 4.  [NF2: ocular, neural and genetic manifestations].

Authors:  M Feucht; V-F Mautner; G Richard
Journal:  Klin Monbl Augenheilkd       Date:  2005-04       Impact factor: 0.700

Review 5.  Neurofibromatosis type 2 (NF2): diagnosis and management.

Authors:  Simon K W Lloyd; D Gareth R Evans
Journal:  Handb Clin Neurol       Date:  2013

6.  Management strategies in neurofibromatosis type 2.

Authors:  David A Moffat; Nicola Quaranta; David M Baguley; David G Hardy; Phillip Chang
Journal:  Eur Arch Otorhinolaryngol       Date:  2002-07-31       Impact factor: 2.503

7.  Age at symptom onset and long-term survival in patients with neurofibromatosis Type 2.

Authors:  Goro Otsuka; Kiyoshi Saito; Tetsuya Nagatani; Jun Yoshida
Journal:  J Neurosurg       Date:  2003-09       Impact factor: 5.115

8.  Multiple synchronous sites of origin of vestibular schwannomas in neurofibromatosis Type 2.

Authors:  Stavros M Stivaros; Anat O Stemmer-Rachamimov; Robert Alston; Scott R Plotkin; Joseph B Nadol; Alicia Quesnel; Jennifer O'Malley; Gillian A Whitfield; Martin G McCabe; Simon R Freeman; Simon K Lloyd; Neville B Wright; John-Paul Kilday; Ian D Kamaly-Asl; Samantha J Mills; Scott A Rutherford; Andrew T King; D Gareth Evans
Journal:  J Med Genet       Date:  2015-06-23       Impact factor: 6.318

9.  Multiple bilateral cranial nerve schwannomas in a patient with neurofibromatosis type 2.

Authors:  Ribhav Pasricha; Sachin Anil Borkar; Kanwaljeet Garg; Leve Joseph; Bhawani Shankar Sharma
Journal:  Asian J Neurosurg       Date:  2016 Apr-Jun

Review 10.  Neurofibromatosis type 2 (NF2): a clinical and molecular review.

Authors:  D Gareth R Evans
Journal:  Orphanet J Rare Dis       Date:  2009-06-19       Impact factor: 4.123

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.